Combination therapy for advanced tonsil cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two targeted drugs (nimotuzumab and toripalimab) with chemotherapy for people with advanced tonsil cancer that can be surgically removed. The goal is to see if this approach works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have tonsil cancer that is locally advanced and can be removed with surgery.
- You have not had previous treatment for advanced tonsil cancer (except certain prior therapies finished at least 6 months ago).
- You are willing to use effective birth control during and for a period after treatment if you or your partner could become pregnant.
- You have good organ function (kidney, liver, blood, and clotting) based on blood tests.
- You do not have active autoimmune disease, HIV, tuberculosis, or other serious uncontrolled health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (penpulimab) with chemotherapy for people with advanced hypopharyngeal cancer that can still be removed with surgery. The goal is to see if this combination shrinks tumors and improves outcomes before surgery.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
This trial tests a new approach to treat throat cancer while trying to preserve your larynx (voice box). It combines chemotherapy drugs and an immunotherapy drug before surgery or radiation. The goal is to see if this can help you avoid needing to have your larynx removed.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.
This trial tests whether giving a type of immunotherapy (PD-1 inhibitor) together with chemotherapy before surgery can help treat advanced laryngeal and hypopharyngeal squamous cell carcinoma. It aims to improve outcomes for patients whose cancer hasn't spread to distant organs.
Hear when a new Head & Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.